STOCK TITAN
  1. Home
  2. News
  3. ARCT

Arcturus Therapeutics Holdings Inc - ARCT STOCK NEWS

Welcome to our dedicated news page for Arcturus Therapeutics Holdings (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therapeutics Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arcturus Therapeutics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arcturus Therapeutics Holdings's position in the market.

News
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
Rhea-AI Summary
Arcturus Therapeutics Holdings Inc. will release its financial results for the first quarter of 2024 on May 8, 2024, focusing on mRNA medicines for infectious diseases and rare liver and respiratory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
Rhea-AI Summary
Arcturus Therapeutics Holdings Inc. announces positive financial results for Q4 2023 and progress in vaccine development and discovery programs. Kostaive® set to launch in Japan, ARCT-032 and ARCT-810 on track for Phase 1b and Phase 2 interim data respectively. New STARR® vaccine discovery programs initiated for Lyme Disease and Gonorrhea. Cash runway extended to Q1 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
earnings
-
News
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
Rhea-AI Summary
Arcturus Therapeutics Holdings Inc. will present at a Fireside Chat hosted by Barclays 26th Annual Global Healthcare Conference. The company focuses on developing infectious disease vaccines and rare disease treatments. The presentation will be available via webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.41%
Tags
conferences
News
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
Rhea-AI Summary
Arcturus Therapeutics Holdings Inc. receives orphan medicinal product designation from the European Commission and FDA for ARCT-032 to treat Cystic Fibrosis. The designation provides various incentives, including market exclusivity and fee reductions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
none
-
News
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
Rhea-AI Summary
Arcturus Therapeutics Holdings Inc. announced the release of its financial results for Q4 and full year 2023, focusing on mRNA medicines, infectious disease vaccines, and rare diseases. The earnings conference call will be held on March 7, 2024, at 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences earnings
-
News
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Rhea-AI Summary
A study conducted by Meiji Seika Pharma in Japan compared ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, with a conventional mRNA COVID-19 vaccine. The data showed that ARCT-154 induces a longer immune response and has an advantage in antibody persistence compared to the conventional vaccine. The study demonstrated the continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of the duration of the immune response. The sa-mRNA technology has the potential to provide significant advancements over conventional mRNA vaccines including prolonged protection at lower doses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
covid-19
News
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Rhea-AI Summary
CSL and Arcturus Therapeutics announce positive results of a Phase 3 study evaluating a booster dose of ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine. The study conducted in Japan demonstrates Immunological Non-Inferiority to Wuhan Strain and Superior Immunogenicity to Omicron BA.4/5 Variant. The new analysis at 6 months post-vaccination shows that ARCT-154 induces a longer immune response compared to Comirnaty for both the original Wuhan strain and Omicron BA.4/5 variant, and an advantage in antibody persistence. The results follow the approval of the world's first sa-mRNA COVID-19 vaccine for adults by Japan Ministry of Health, Labor and Welfare in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
covid-19
-
News
PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems
Rhea-AI Summary
PassPort Technologies, Inc. (PPTI) collaborates with Arcturus Therapeutics (ARCT) to evaluate innovative mRNA formulations and transdermal delivery mechanisms for vaccines and therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
none
-
News
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Rhea-AI Summary
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA (sa-mRNA) vaccine, elicited a numerically higher immune response against the original Wuhan-Hu-1 virus strain and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared to a booster dose of the conventional mRNA vaccine Comirnaty®. ARCT-154 results were achieved with one sixth the dose of Comirnaty® (5 μg vs 30 μg). The study included healthy adults initially immunized with two doses of an mRNA vaccine (Comirnaty® or Spikevax™) and then a third dose of Comirnaty® at least three months prior to the booster dose of either ARCT-154 or Comirnaty® in the study. Both vaccines were well-tolerated, with no causally associated severe or serious adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
News
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Rhea-AI Summary
CSL and Arcturus Therapeutics Announce Positive Phase 3 Results for ARCT-154 Sa-mRNA COVID-19 Vaccine
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
Stock ARCT logo
Arcturus Therapeutics Holdings Inc

Nasdaq:ARCT

ARCT Rankings

#2685 Ranked by Market Cap
#1763 Ranked by Stock Gains
N/A Ranked by Dividends

ARCT Stock Data

810.95M
24.55M
8.75%
92.12%
17.87%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
San Diego

About ARCT

founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.